Expression Pathology
Expression Pathology Changes Name to OncoPlex Diagnostics, Plans 2012 Launch of Lung Cancer Test
Premium
Clinical proteomics firm Expression Pathology has changed its name to OncoPlex Diagnostics and opened a CLIA laboratory in Rockville, Md.
Expression Pathology, MD Anderson Evaluating Technology for Lung Cancer Therapy Selection
NEW YORK (GenomeWeb News) – Expression Pathology today announced a collaboration with the University of Texas MD Anderson Cancer Center for the evaluation of the company's Liquid Tissue SRM technology.
Theranostics Health Launching Alternative to Formalin for Preserving Phosphoproteomic Tissue Samples
Premium
By Adam Bonislawski
Theranostics Health has licensed a new fixative developed by researchers at George Mason University that could significantly improve the quality of tissue samples available to proteomic researchers.
Under the terms of the deal, Expression Pathology will use its Liquid Tissue SRM technology to develop multiplexed quantitative mass spectrometry assays for the detection of cancer signaling pathway proteins in FFPE tissue samples.
Roche Pharma to Use Expression Pathology's Assays
Roche will use the company's multiplexed quantitative assays of cancer signaling pathway proteins.
Dec 18, 2009
Movers & Shakers: Dec 18, 2009
Premium
Nov 20, 2009
Nov 18, 2009